Trial Profile
Relative Bioavailability of 10 mcg Olodaterol (Solution for Inhalation Administered With the Respimat) at Steady State Alone or in Combination With Multiple Doses of 400 mg q.d. Fluconazole (Hard Capsule) in Healthy Male and Female Volunteers (an Open Label, Fixed Sequence, Phase I Study).
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 18 Jul 2014
Price :
$35
*
At a glance
- Drugs Olodaterol (Primary) ; Fluconazole
- Indications Asthma; Chronic obstructive pulmonary disease
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 19 Aug 2010 Actual patient number is 35 as reported by ClinicalTrials.gov.
- 19 Aug 2010 Actual end date (July 2010) added as reported by ClinicalTrials.gov.
- 19 Aug 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.